Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen

AIDS

Volumn 19, Issue 3, 2005, Pages 319-330

  Olsen, Christian Holkmann ^a,i   Gatell, Jose ^b   Ledergerber, Bruno ^c   Katlama, Christine ^d   Friis Møller, Nina ^a   Weber, Jonathan ^e   Horban, Andrzéj ^f   Staszewski, Schlomo ^g   Lundgren, Jens D ^a   Phillips, Andrew N ^h  

^a Copenhagen HIV Programme ^*  (Denmark)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ST MARY S HOSPITAL   (United Kingdom)

^f Wojewodzki Szpital Zakazny   (Poland)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

Author keywords

AIDS; Combination antiretroviral therapy; Death; Observational study; Surrogate marker

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL OBSERVATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 20144366701     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Antiviral Drugs Advisory Committee. Meeting Start Date: 14th July 1997. Transcripts made 140797 and 150797. Web publication last seen on 4th of March 2004 at http://www.fda.gov/ohrms/dockets/ac/cder97t. htm#Antiviral%20Drugs%20Advisory%20Committee.
2. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses 2000; 16:1123-1133.
3. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
4. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-1832.
5. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40-47.
6. Montaner JS, DeMasi R, Hill AM. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998; 12:F23-F28.
7. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
8. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426-431.
9. Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, et al. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. AIDS 1997; 11:169-175.
10. D'Arminio MA, Testori V, Adorni F, Castelnuovo B, Bini T, Testa L, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13:1669-1676.
11. Chene G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, et al. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. AIDS 1998; 12:2313-2320.
12. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130:570-577.
13. Miller V, Staszewski S, Nisius G, Lepri AC, Sabin C, Phillips AN. Risk of new AIDS diseases in people on triple therapy. Lancet 1999; 353 (9151):463.
14. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353 (9156):863-868.
15. Grabar S, Le M, V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
16. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001; 135:954-964.
17. De G, V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J Infect Dis 1997; 175:237-246.
18. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-613.
19. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active anti-retroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186:1023-1027.
20. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379-386.
21. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11:611-616.
22. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-85.
23. Seth A, Markee J, Hoering A, Sevin A, Sabath DE, Schmitz JE, et al. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent anti-retroviral therapy. J Infect Dis 2001; 183:722-729.
24. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
25. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180:448-453.
26. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus confection. Lancet 2003; 362 (9397):1708-1713.
27. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315 (7117):1194-1199.
28. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352 (9142):1725-1730.
29. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362 (9377):22-29.
30. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active anti-retroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-1626.
31. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
32. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 1-19.
33. Kirkwood JM. Essential Medical Statistics. Blackwell Science; 2003.
34. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT.in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-191.
35. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996; 348(9023):283-291.
36. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Coup Study 175 Study Team. N Engl J Med 1996; 335:1081-1090.
37. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349(9063): 1413-1421.
38. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
39. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351 (9102): 543-549.
40. Sterling TR, Hawkins DA, Clumeck N, Cooper DA, Myers R, Delfraissy JF. Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients. Clin Drug Invest 2000; 20:295-307.
41. Li Q, Schacker T, Carlis J, Beilman G, Nguyen P, Haase AT. Functional genomic analysis of the response of HIV-1 -infected lymphatic tissue to antiretroviral therapy. J Infect Dis 2004; 189:572-582.
42. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406-412.
43. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997; 16:1965-1982.
44. Walker AS, Peto TE, Babiker AG, Darbyshire JH. Markers of HIV infection in the Concorde trial. Concorde Co-ordinating Committee. QJM 1998; 91:423-438.
45. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-197.
46. Lundgren JD, Vella S, Paddam L, Blaxhult A, Vetter N, Clumeck N, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA Study. Ninth Conference on Retroviruses and Opportunistic Infections, Boston, 2002.
47. Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002; 155:760-770.
48. Autran B, Carcelaint G, Li TS, Gorochov G, Blanc C, Renaud M, et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999; 66:207-211.
49. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco G, Muratori DS, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999; 13:1187-1193.
50. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-3387.
51. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360 (9327):119-129.
52. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio MA, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185:178-187.
53. Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337 (8738):389-392.
54. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671.